Mid-afternoon market update: Dow tumbles over 200 points, BELLUS Health shares spike higher


Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 50,801,450 cases with around 817,950 deaths. India confirmed a total of at least 34,697,860 cases and 475,630 deaths, while Brazil reported over 22,189,860 COVID-19 cases with 616,940 deaths. In total, there were at least 270,510,600 cases of COVID-19 worldwide with more than 5,324,320 deaths.

Leading and Lagging Sectors

Real estate shares climbed 1.4% on Monday. Meanwhile, top gainers in the sector included Condor Hospitality Trust, Inc. CDOR +8.17% (Get Free Alerts for CDOR), up 8% and Nam Tai Property Inc. NTP +7.13% (Get Free Alerts for NTP) up 6%.

In trading on Monday, energy shares fell 2.5%.

Top Headline

Pfizer Inc PFE +4.62% agreed to acquire Arena Pharmaceuticals Inc ARNA +80.38%, a clinical-stage company developing therapies to treat several immuno-inflammatory diseases.

Under the agreement terms, Pfizer will acquire Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.

Equities Trading UP

Arena Pharmaceuticals, Inc. ARNA +80.38% shares shot up 80% to $89.80. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.

Shares of BELLUS Health Inc. BLU +48.21% got a boost, shooting 52% to $8.49 after the company announced topline data from its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. The data showed that the 50 mg and 200 mg BID doses of BLU-5937 achieved statistical significance on the primary endpoint with a 34% placebo-adjusted reduction in 24-hour cough frequency observed at day 28. 

Foghorn Therapeutics Inc. FHTX +54.96% shares were also up, gaining 34% to $16.05. Loxo Oncology, an R&D group of Eli Lilly And Co LLY +1.87%, and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platform.

Equities Trading DOWN

Nisun International Enterprise Development Group Co., Ltd NISN -60.29% shares tumbled 60% to $4.42 after the company priced its $77 million underwritten public offering of common shares and pre-funded warrants to purchase common shares.

Shares of IGM Biosciences, Inc. IGMS -41.31% were down 46% to $26.88 after reporting Phase 1 trial data in advanced B-Cell malignancies. RBC Capital downgraded IGM Biosciences to Sector Perform from Outperform with a price target of $51, down from $90.

Blonder Tongue Laboratories, Inc. BDR -30.8% was down, falling 31% to $0.60 after the NYSE American said it will commence delisting proceedings against Blonder Tongue Laboratories.

Commodities

In commodity news, oil traded down 0.1% to $71.64, while gold traded up 0.2% to $1,789.10.

Silver traded up 0.6% Monday to $22.325 while copper rose 0.1% to $4.2870.

Euro zone

European shares closed lower today. The eurozone’s STOXX 600 slipped 0.43%, the Spanish Ibex Index fell 0.45% and the German DAX 30 slipped 0.01%. Meanwhile, the London’s FTSE 100 fell 0.83%, French CAC 40 fell 0.70% and Italy’s FTSE MIB fell 0.64%.

Wholesale prices in Germany surged 16.6% year-over-year in November following a 15.2% increase a month ago.

Economics

There were no major US economic releases Monday.

Benzinga does not provide investment advice. All rights reserved.

Recommended Content


Recommended Content

Editors’ Picks

EUR/USD keeps bullish vibe, first upside target emerges near 1.1400

EUR/USD keeps bullish vibe, first upside target emerges near 1.1400

EUR/USD holds steady near 1.1360 in Monday’s Asian session. The positive view of the pair prevails above the key 100-day EMA with the bullish RSI indicator. The Greenback steadies as traders are confused by mixed signals on US-China trade relations.

EUR/USD News
GBP/USD consolidates around 1.3300 mark; downside potential seems limited

GBP/USD consolidates around 1.3300 mark; downside potential seems limited

GBP/USD lacks any firm intraday direction and oscillates in a range at the start of a new week. The USD preserves last week’s recovery gains from a multi-year low and acts as a headwind. Bets for a less dovish BoE and hopes for a UK-US trade deal to limit the downside for the major.

GBP/USD News
Gold price languishes below $3,300; last week’s swing low holds the key for bulls

Gold price languishes below $3,300; last week’s swing low holds the key for bulls

Gold price meets with a fresh supply on Monday amid the US-China trade deal optimism. A fall in China’s gold consumption and a modest USD uptick also weigh on the commodity. Trade-related uncertainties and Fed rate cut bets warrant caution for the XAU/USD bears.

Gold News
Bitcoin and Ethereum stabilize while Ripple shows strength

Bitcoin and Ethereum stabilize while Ripple shows strength

Bitcoin and Ethereum prices are stabilizing at around $93,500 and $1,770 at the time of writing on Monday, following a rally of over 10% and 12% the previous week. Ripple price also rallied 8.3% and closed above its key resistance level last week, indicating an uptrend ahead.

Read more
Week ahead: US GDP, inflation and jobs in focus amid tariff mess – BoJ meets

Week ahead: US GDP, inflation and jobs in focus amid tariff mess – BoJ meets

Barrage of US data to shed light on US economy as tariff war heats up. GDP, PCE inflation and nonfarm payrolls reports to headline the week. Bank of Japan to hold rates but may downgrade growth outlook. Eurozone and Australian CPI also on the agenda, Canadians go to the polls.

Read more
The Best brokers to trade EUR/USD

The Best brokers to trade EUR/USD

SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.

Read More

Majors

Cryptocurrencies

Signatures

Best Brokers of 2025